Paper36924778
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S and 10 others. Lancet, 2023. Cited by 199 papers, by iCite.
Cite this record
ConductScience Library. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Papers, record 36924778. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36924778
- Disease
- Hot flashes47 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Neurokinin-3 | Major topic |
| Quality of Life | Major topic |
| Humans | |
| Female | |
| Treatment Outcome | |
| Menopause | |
| Double-Blind Method | |
| Heterocyclic Compounds, 2-Ring | |
| Thiadiazoles |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04003155 | A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06957691 | Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy | Background | ClinicalTrials.gov | |
| NCT07042516 | Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 36924777 | Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms. | https://conductscience.org/library/papers/36924777 |
Source PubMed
Cited by92
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 199 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42902266 | Efficacy and safety of non-hormonal pharmacotherapies for depressive and anxiety symptoms during the menopausal transition and postmenopause: a systematic review. | BMC Psychiatry | 2026 | https://conductscience.org/library/papers/42902266 | PubMed |
| 42888352 | Population pharmacokinetic-pharmacodynamic modeling and dose selection of GS1-144 based on luteinizing hormone suppression in postmenopausal women. | J Pharmacokinet Pharmacodyn | 2026 | https://conductscience.org/library/papers/42888352 | PubMed |
| 42862303 | [Perimenopause and postmenopause: acute diagnostic and therapeutic aspects for the DACH region : Consensus paper of the Austrian Society for Gynecology and Obstetrics (OEGGG), the German Society for Gynecology and Obstetrics (DGGG), the German Menopause Society (DMG) and the Swiss Society for Gynecology and Obstetrics (SGGG)]. | Wien Klin Wochenschr | 2026 | https://conductscience.org/library/papers/42862303 | PubMed |
| 42831287 | NK2R signaling governs intestinal lipid mobilization and mucosal inflammation. | Elife | 2026 | https://conductscience.org/library/papers/42831287 | PubMed |
| 42681820 | Microvascular endothelial function is blunted in postmenopausal females with frequent hot flushes. | Exp Physiol | 2026 | https://conductscience.org/library/papers/42681820 | PubMed |
| 42654471 | Vasomotor Symptoms and Their Association with Depressive and Anxiety Symptoms in Peri- and Postmenopausal Women: A Systematic Review of Observational Studies. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42654471 | PubMed |
| 42609071 | Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper. | Int J Gynaecol Obstet | 2026 | https://conductscience.org/library/papers/42609071 | PubMed |
| 42603995 | Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021. | Gynecol Oncol Rep | 2026 | https://conductscience.org/library/papers/42603995 | PubMed |
| 42580842 | Role of menopause in the development of cardiovascular disease in women. | Open Heart | 2026 | https://conductscience.org/library/papers/42580842 | PubMed |
| 42575966 | Menopause and neurological disorders: a roadmap for research. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/42575966 | PubMed |
| 42519421 | A brain-first framework for perimenopause management: the case for non-invasive neuromodulation. | Front Glob Womens Health | 2026 | https://conductscience.org/library/papers/42519421 | PubMed |
| 42458154 | Women's Treatment Preferences for Moderate to Severe Vasomotor Symptoms Associated with Menopause: Insights from the WARMER Study. | Patient | 2026 | https://conductscience.org/library/papers/42458154 | PubMed |
| 42326829 | TACR3 variant confers resilience to aging and Alzheimer's disease. | medRxiv | 2026 | https://conductscience.org/library/papers/42326829 | PubMed |
| 42171669 | Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE). | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/42171669 | PubMed |
| 42160911 | Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant. | Breast | 2026 | https://conductscience.org/library/papers/42160911 | PubMed |
| 42137787 | Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. | J Endocr Soc | 2026 | https://conductscience.org/library/papers/42137787 | PubMed |
| 42115840 | Flushing: Neuroendocrine Mechanisms and a Structured Diagnostic Approach. | Clin Endocrinol (Oxf) | 2026 | https://conductscience.org/library/papers/42115840 | PubMed |
| 41998196 | The effect of acupuncture on hot flashes and sleep disturbances in women with breast cancer receiving endocrine therapy: a pre-post quasi-interventional study. | Support Care Cancer | 2026 | https://conductscience.org/library/papers/41998196 | PubMed |
| 41981275 | Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation. | Nat Rev Endocrinol | 2026 | https://conductscience.org/library/papers/41981275 | PubMed |
| 41979542 | Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial. | Menopause | 2026 | https://conductscience.org/library/papers/41979542 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| FEZOLINETANT | CHEMBL3608680 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3608680 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36924778
GET https://conductscience.org/api/papers/v1/36924778/cited_by?page=2